VanEck Associates’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-20,917
| Closed | -$2.19M | – | 1378 |
|
|
2026
Q1 | $2.19M | Sell |
20,917
-88,209
| -81% | -$9.08M | ﹤0.01% | 970 |
|
|
2025
Q4 | $11.1M | Sell |
109,126
-5,813
| -5% | -$467K | 0.01% | 533 |
|
|
2025
Q3 | $6.29M | Sell |
114,939
-5,860
| -5% | -$293K | 0.01% | 682 |
|
|
2025
Q2 | $6.42M | Sell |
120,799
-6,792
| -5% | -$345K | 0.01% | 631 |
|
|
2025
Q1 | $5.52M | Buy |
127,591
+4,749
| +4% | +$240K | 0.01% | 673 |
|
|
2024
Q4 | $6.9M | Sell |
122,842
-13,023
| -10% | -$810K | 0.01% | 581 |
|
|
2024
Q3 | $9.55M | Sell |
135,865
-17,484
| -11% | -$987K | 0.01% | 457 |
|
|
2024
Q2 | $6.48M | Buy |
153,349
+7,785
| +5% | +$428K | 0.01% | 512 |
|
|
2024
Q1 | $10.1M | Buy |
145,564
+5,174
| +4% | +$327K | 0.02% | 400 |
|
|
2023
Q4 | $10.4M | Sell |
140,390
-9,078
| -6% | -$595K | 0.02% | 361 |
|
|
2023
Q3 | $10.2M | Sell |
149,468
-16,345
| -10% | -$1.39M | 0.02% | 341 |
|
|
2023
Q2 | $15.6M | Sell |
165,813
-1,969
| -1% | -$154K | 0.03% | 286 |
|
|
2023
Q1 | $11.4M | Sell |
167,782
-30,116
| -15% | -$1.94M | 0.03% | 325 |
|
|
2022
Q4 | $9.8M | Buy |
197,898
+68,538
| +53% | +$2.8M | 0.03% | 340 |
|
|
2022
Q3 | $4.2M | Sell |
129,360
-47,410
| -27% | -$1.95M | 0.01% | 470 |
|
|
2022
Q2 | $6.96M | Sell |
176,770
-5,638
| -3% | -$301K | 0.02% | 387 |
|
|
2022
Q1 | $12.8M | Buy |
182,408
+116
| +0.1% | +$8.48K | 0.03% | 324 |
|
|
2021
Q4 | $14.2M | Sell |
182,292
-13,301
| -7% | -$1.17M | 0.03% | 306 |
|
|
2021
Q3 | $18.7M | Sell |
195,593
-15,920
| -8% | -$1.68M | 0.05% | 252 |
|
|
2021
Q2 | $26.3M | Buy |
211,513
+42,417
| +25% | +$5.06M | 0.06% | 225 |
|
|
2021
Q1 | $22.3M | Buy |
169,096
+5,379
| +3% | +$736K | 0.06% | 213 |
|
|
2020
Q4 | $21.7M | Sell |
163,717
-21,095
| -11% | -$2.55M | 0.06% | 199 |
|
|
2020
Q3 | $18.8M | Sell |
184,812
-31,108
| -14% | -$2.69M | 0.06% | 190 |
|
|
2020
Q2 | $18.8M | Buy |
215,920
+30,677
| +17% | +$2.45M | 0.07% | 183 |
|
|
2020
Q1 | $10.7M | Sell |
185,243
-4,214
| -2% | -$342K | 0.05% | 203 |
|
|
2019
Q4 | $17.5M | Buy |
189,457
+52,679
| +39% | +$4.63M | 0.07% | 191 |
|
|
2019
Q3 | $12.4M | Sell |
136,778
-3,950
| -3% | -$450K | 0.06% | 200 |
|
|
2019
Q2 | $16.6M | Sell |
140,728
-72,333
| -34% | -$7.29M | 0.08% | 180 |
|
|
2019
Q1 | $18.5M | Sell |
213,061
-38,286
| -15% | -$3.26M | 0.09% | 169 |
|
|
2018
Q4 | $15.9M | Sell |
251,347
-7,454
| -3% | -$512K | 0.08% | 187 |
|
|
2018
Q3 | $20.4M | Buy |
+258,801
| New | +$16.9M | 0.1% | 178 |
|
Other funds holding EXAS
VanEck Associates's EXAS Position: Q2 2026 in Review
VanEck Associates sold out of Exact Sciences (EXAS) in Q2 2026, closing a stake of 20,917 shares — an estimated $2.19M sold.
VanEck Associates first reported a position in EXAS in Q3 2018 and held it in 31 quarters. The position peaked at $26.3M in Q2 2021. 1 fund tracked by Wall St. Rank holds EXAS as of Q2 2026.
- VanEck Associates reported no remaining Exact Sciences position as of Q2 2026 after selling out during the quarter.
- VanEck Associates sold 20,917 Exact Sciences shares in Q2 2026, an estimated $2.19M.
- VanEck Associates first reported a position in Exact Sciences in Q3 2018 and held it in 31 quarters.
- VanEck Associates's Exact Sciences position peaked at $26.3M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Exact Sciences as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.